GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovaro Inc (NAS:RENB) » Definitions » 3-Year EPS without NRI Growth Rate

Renovaro (Renovaro) 3-Year EPS without NRI Growth Rate : -11.80% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Renovaro 3-Year EPS without NRI Growth Rate?

Renovaro's EPS without NRI for the three months ended in Dec. 2023 was $-0.07.

During the past 3 years, the average EPS without NRI Growth Rate was -11.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was -17.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was -46.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 12 years, the highest 3-Year average EPS without NRI Growth Rate of Renovaro was 8.00% per year. The lowest was -207.20% per year. And the median was -23.00% per year.


Competitive Comparison of Renovaro's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Renovaro's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Renovaro's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Renovaro's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Renovaro's 3-Year EPS without NRI Growth Rate falls into.



Renovaro 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Renovaro  (NAS:RENB) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Renovaro 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Renovaro's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Renovaro (Renovaro) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovaro Inc (NAS:RENB) » Definitions » 3-Year EPS without NRI Growth Rate
Traded in Other Exchanges
Address
2080 Century Park East, Suite 906, Los Angeles, CA, USA, 90067
Renovaro Biosciences Inc Formerly Enochian BioSciences Inc is a biopharmaceutical company. It is engaged in the research and development of pharmaceutical and biological products for the treatment of HIV, HBV, and cancer with the intent to manufacture said products.
Executives
Leni Boeren director 2080 CENTURY PARK EAST, #906, LOS ANGELES CA 90067
Ruud Hendriks director CHATEAU D'AZUR, BLVD D'LTALIE 44, MONACO O9 C11298000
Ole Abildgaard 10 percent owner VEDBAEK STRANDVEJ 506, VEDBAEK G7 2950
Francois Binette officer: Executive Vice President 2022 N. ALVARADO STREET, LOS ANGELES CA 90039
Serhat Gumrukcu 10 percent owner 2080 CENTURY CITY EAST, SUITE 906, LOS ANGELES CA 90067
Rene Sindlev director, 10 percent owner FRUEBJERGVEJ 3 BOX 62, COPENHAGEN G7 2100
Carl Forest Sandler other: Former director see note below 330 EAST 33RD STREET, APARTMENT 3A, NEW YORK FL 10016
Jayne Mcnicol director 606 NORTHERN AVENUE, MILL VALLEY CA 94941
Gregg H Alton director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Carol L Brosgart director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Henrik Gronfeldt-sorensen director STUMPEDYSSEVEJ 17, HORSHOLM G7 2970
Luisa Puche officer: Chief Financial Officer 318 NE 104TH STREET, MIAMI FL 33138
Luc Debruyne director NOORDENWINDHELLING 2 02/05, OOSTDUINKERKE C9 8670
Anderson Wittekind William 10 percent owner 8581 SANTA MONICA BLVD, LOS ANGELES CA 90069
Leire, Eric Jean Marie director, officer: CEO; President C/O DANDRIT BIOTECH USA, INC., P.O. BOX 189, RANDOLPH VT 05060